North America Anti-venom Market Size & Outlook, 2024-2030
The anti-venom market in North America is expected to reach a projected revenue of US$ 749.9 million by 2030. A compound annual growth rate of 7.9% is expected of North America anti-venom market from 2024 to 2030.
Revenue, 2023 (US$M)
$444.3
Forecast, 2030 (US$M)
$749.9
CAGR, 2024 - 2030
7.9%
Report Coverage
North America
North America anti-venom market highlights
- The North America anti-venom market generated a revenue of USD 444.3 million in 2023.
- The market is expected to grow at a CAGR of 7.8% from 2024 to 2030.
- In terms of segment, snake was the largest revenue generating species in 2023.
- Snake is the most lucrative species segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 444.3 million |
| Market revenue in 2030 | USD 749.9 million |
| Growth rate | 7.8% (CAGR from 2023 to 2030) |
| Largest segment | Snake |
| Fastest growing segment | Snake |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Snake |
| Key market players worldwide | Bristol-Myers Squibb Co, Celgene, Eisai Co Ltd, Phaxiam, Roche Holding AG, Genmab A/S, GlaxoSmithKline, Novartis AG ADR, Pfizer Inc, Sanofi SA |
Other key industry trends
- In terms of revenue, North America region accounted for 37.7% of the global anti-venom market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 507.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Venom Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Genmab A/S | View profile | 2266 | Carl Jacobsens Vej 30, Valby, Denmark, 2500 | https://www.genmab.com |
| Phaxiam | View profile | 51-100 | Lyon, Rhone-Alpes, France, Europe | https://phaxiam.com |
| GlaxoSmithKline | View profile | 10001+ | London, England, United Kingdom, Europe | http://www.gsk.com |
| Celgene | View profile | 10001+ | Summit, New Jersey, United States, North America | https://www.bms.com |
| Eisai Co Ltd | View profile | 11076 | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088 | http://www.eisai.co.jp |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
